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ABSTRACT
Objective. To provide a state of the art 
of economic analyses applied to rheu-
matoid arthritis (RA).
Methods. A systematic literature re-
view on economic consequences and 
pharmacoeconomic issues of RA was 
performed.
Results. 127 valid articles were exam-
ined in this review. Generally, the ﬁ-
nancial impact of RA is substantial for 
health-care systems and society world-
wide, although differences exist among 
national economies. Both direct and 
indirect (i.e. loss of productivity) costs 
contribute to economic burden of RA 
and must be taken into account when 
estimating overall impact to society. 
Disease severity, disease activity, age 
and socioeconomic status have been 
found to be the most relevant predic-
tors of cost increase in RA. Moreover, 
introduction of biological anti-rheu-
matic agents has signiﬁcantly raised 
direct medical costs in certain patients, 
but has also led to marked improve-
ments in reducing disease activity, joint 
damage, and productivity loss in many 
of these patients. RA has also a signiﬁ-
cant impact on all aspects of quality of 
life; recent publications on health util-
ity scores showed RA to be one of the 
diseases associated with poorest qual-
ity of life.
Conclusions. RA represents a clinical 
and economic burden for healthcare 
systems. Although attributable RA 
costs have been extensively evaluated 
over the last decades, several issues, 
especially concerning the use of expen-
sive therapies, must be addressed and 
frequently updated. Future research 
should also provide health economic 
evidence from usual practice settings, 
and on the economic impact of differ-
ent therapeutic approaches to pursue 
speciﬁc clinical targets in individual 
patients. 
Introduction
Rheumatoid arthritis (RA) is a chronic 
systemic autoimmune disease affecting 
approximately 0.05–1% of the popula-
tion (1, 2). The course of RA is vari-
able, but for a substantial proportion of 
patients it is characterised by persistent 
pain and stiffness, progressive joint de-
struction, functional disability, and pre-
mature mortality (3). RA also presents 
a serious socio-economic burden in 
terms of both direct medical and non-
medical costs, and indirect costs (i.e. 
productivity loss, premature mortality, 
and burden for caregivers) (4-9). 
The introduction of early therapy with 
disease-modifying anti-rheumatic drugs 
(DMARDs), particularly widespread 
use of methotrexate, led to substantial 
improvement in status of many patients. 
Nonetheless, about 10–40% of patients 
have incomplete responses to meth-
otrexate and other DMARDs, for whom 
biological therapies have led to marked 
improvements in disease activity con-
trol and prevention of joint damage. 
However, biological therapies are far 
more costly than traditional DMARDs, 
and the higher direct medical costs limit 
prescription of biologic agents in RA. 
Market access conditions such as reim-
bursement status, level of co-payment, 
prescribing restrictions, will impact 
payers’ level of acceptance of biologic 
agents for speciﬁc patients. As per-
capita healthcare expenditures reﬂect 
payers’ willingness to pay, prescription 
of biological drugs is much more devel-
oped in high-income countries (10).
The high societal costs of RA and new 
biological therapies have led healthcare 
payers and providers to increase their 
level of attention on this condition, par-
ticularly in the current period of budget 
constraints. By using cost-effective-
ness analysis to evaluate the economic 
“value” of a drug, public payers dictate 
to some extent what treatments can 
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or cannot be charged on their budget. 
This is particularly important in the 
RA treatment landscape, where few pa-
tients could afford costs of biological 
therapies without health insurance, be 
it public or private.
In particular, GRADE (Grading of 
Recommendations Assessment, Devel-
opment and Evaluation) encourage in-
corporation of economic issues in RA 
recommendations regarding treatment 
(11). We systematically reviewed ex-
isting economic studies in RA to better 
understand the economic consequences 
of this disease and its treatment, as pre-
sented in this report.
Materials and methods
Search strategy and inclusion /
exclusion criteria
To collect and review the evidence, we 
performed a systematic literature re-
view aimed to select economic evalu-
ations in RA. In order to focus on the 
most recent clinical practice, we in-
cluded studies, analyses and reviews 
on RA economic topics published over 
the last 5 years (from May 2007 until 
June 2012) through a MEDLINE search 
(however some publications older than 
5 years mentioned in selected reviews 
could have been reported in this arti-
cle). As the aim of the review was to 
perform an assessment of therapeutic 
classes and not active principles indi-
vidually, head-to-head studies compar-
ing single active principles were not 
included. To maximise retrieval of all 
pertinent papers we applied medical 
subject headings (“MeSH” terms), or 
keyword searches when at all appropri-
ate. Box 1 and Table 1 provide details 
of the search strategy. After scanning all 
titles and abstracts, we retrieved the full 
text for all potentially relevant studies. 
Data review and analysis
Two members of the review team ex-
amined studies in a three-step proc-
ess. First, the title list was considered; 
second, abstracts of those that passed 
the title review were examined; third, 
potentially relevant articles were re-
viewed. Disagreement between the two 
reviewers was resolved by consensus of 
a third party. Data from eligible studies 
were extracted and a spreadsheet was 
used for data entry. The articles were 
also categorised according the classiﬁ-
cation illustrated in Figure 1. 
Results
We screened 505 non-duplicate cita-
tions (last update: May 25, 2012), 378 
of which (74.9%) were excluded as they 
did not meet pre-deﬁned inclusion crite-
ria. 127 economic evaluations were in-
cluded, 19 of which (15%) were reviews. 
Research details are shown in Figure 1. 
These retrieved articles were NOT hand 
searched for further references.
Results
Costs of RA
A large number of economic evalua-
tions have been performed in recent 
years to assess the burden of RA for 
patients, healthcare providers (public 
and private), and society in general. Ta-
bles II and III summarise main ﬁndings 
with regard of direct and indirect costs. 
Of course, methodological approaches 
and primary objectives vary consider-
ably across these studies, so that a ho-
mogenous comparison is complex and 
difﬁcult to perform, but a comprehen-
sive overview may be informative.
Some recent reviews attempted to com-
pare RA costs across different countries 
or to calculate average costs combining 
results of national studies. Boonen et 
al. (23) performed a systematic review 
of 26 cost-of-illness studies, mainly 
conducted in Western Europe, with the 
aim to derive a weighted average an-
nual cost of RA. Considering the differ-
ent data sources and weighting results 
by the timing of the study, the authors 
found that annual healthcare and non-
healthcare costs were €4,170 (inter-
quartile range: €2,756–€4,561), with 
out-patient costs being the cost driver 
(€2,981). Another systematic review of 
RA costs across different countries was 
reported by Lundkvist et al., in their in 
2008 (2). Annual total economic burden 
(direct costs + indirect costs + informal 
care), was estimated to be €41.631 bil-
lion in the US, and €45.263 billion in 
Box 1 Search terms and strings 
(“rheumatoid arthritis”[TIAB]) AND (“cost” OR “economic” OR “cost of illness” OR “burden” 
[TIAB]) AND (“Humans”[Mesh])
Table I. Search inclusion/exclusion criteria.
Inclusion Exclusion
Including quantitative assessment Including qualitative assessment only
Informing about the economic impact of RA Article non in English
Informing about the economic analysis  of RA treatments Head-to-head drug pharmacoeconomic  
 comparisons
Published from May 2007 until June 2012 Published before May 2007
Fig. 1. Strategy search results*. 
*The sum of articles by category is not equal to 127 as some categories are not mutually exclusive.
**Includes cost-effectiveness, cost-utility, cost-beneﬁt, cost-minimisation and budget impact analyses.
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Table II. Main ﬁndings from studies evaluating direct costs in RA*.
Main Author Year of publication Summary of results Methodological notes 
 (Country) 
Lee TJ (12) 2012 (South Korea) Total annual costs by functional severity: - Class I: Evaluation of direct medical + non-medical + 
  4,230,204 Korean won - Class II: 7,250,674 Korean won indirect costs (societal perspective)  
  - Class III: 8,046,434 Korean won - Class IV: 8,206,215 
  Korean won  
Simons WR (13) 2012 (USA) Per patient annual costs by year: - $4,422: year I   Evaluation of healthcare direct costs during
  - $2,902: year II - $1,882 year III three consecutive years
McBride S (19) 2011 (USA) Per patient annual costs: - Group 1 (patients receiving Evaluation of drug costs and total healthcare 
  a single anti-TNF: drug costs=$7,058; RA related costs (during ﬁrst year since anti-TNF initiation) 
  costs=$13,312 - Group 2: patients switching from anti- 
  TNF: drug costs=$8,340; RA related costs=$15,048  
  - Costs in Group 2 were signiﬁcantly higher than in      
  Group 1    
Metsios GS (21) 2011 (UK) Signiﬁcant predictors (p<0.05) of increased number Evaluation of hospital number of admissions and 
  of hospital admissions / increased length of stay: hospital length of stay (regression analysis) 
  - Disease activity (measured with disease activity score:     
  DAS28) - Physical activity (measured with International
  Physical Activity Questionnaire)   
Zhu TY (26) 2011 (Hong Kong) Per patient annual costs: - Total costs: US$ 9,286 - Direct Longitudinal evaluation  (follow-up=10.8 years) 
  costs: 40% of total costs  of direct + indirect costs
Kirchhoff T (28) 2011 (Germany) Per patient annual costs: - Total costs (direct + indirect): Evaluation of direct medical + indirect costs 
  €4,280 in 1997-98; €3,830 in 2002 (p>0.05 for the (societal perspective) in two different periods: 
  difference) - Higher costs in 2002 (vs. 1997-98; p<0.001) 1997-98 vs. 2002 
  for medications and hospitalisations     
Beresniak A (29) 2011 (France) Per patient 6-months costs: - Remitted patients (DAS28 Evaluation of 6-months direct costs (excluding 
  ≤ 2.6): €771 - Low disease activity state (DAS28 ≤3.2): drugs), by disease severity (measured with 
  €905 - Moderate to high disease activity (DAS28 >3.2): Disease Activity Score 28-joint count)
  €1,215   
Maravic M (31) 2011 (France) Management costs: - Overall impact 2007: €222 million - Real-life evaluation of drug costs in RA patients 
  Per patient impact (2007): range €6,451-19,618  biotherapies (adalimumab, etanercept, inﬂiximab)
Brach M (32) 2011 (Switzerland) Per patient annual direct costs: - CET: €7,945.34 - SET: Evaluation of direct costs in two different groups 
  €5,619.25  of patients (cognitive-behavioural group therapy,  
   CET, and supportive-experiential group therapy,  
   SET)
Franke LC (35) 2009 (Netherlands) Per patient annual costs: - RA: €14,906 - Ankylosing Comparison of direct medical + family burden + 
  spondylitis: €9,374 indirect costs (societal perspective) in RA vs. 
   ankylosing spondylitis
Boonen A (36) 2009 (Netherlands) Qualitative assessment: - RA is associated to higher direct Evaluation of direct and indirect cost predictors in  
  costs than ankylosing spondylitis - Main cost predictor of RA and ankylosing spondylitis 
  increased costs: reduced physical  activity 
Saraux A (37) 2010 (France) Per patient 6 months direct costs: - Patients remitted/ Evaluation of 6-months direct costs, by
  achieving low disease activity: €905 - Patients NOT achievement of remission/or low disease activity 
  achieving low disease activity: €1,215   
Kobelt G (38) 2009 (Sweden) Direct + indirect costs over 10-year period: - US$336,000 Modelling the 10-year direct + indirect costs of RA  
   patients receiving biological drugs 
Tanaka E (41) 2009 (Japan) Out-patient healthcare costs: - JPY271,498 in 2000 - Evaluation of out-patient healthcare costs before 
  JPY292,417 in 2004 - +7.7% increase from 2000 to 2004 introduction of biological therapies (from 2000 
  - Predictors of increased out-patient costs: aging, longer to 2004)    
  RA duration,  higher Disease Activity Score of 28 Joints    
  (DAS28), and higher Health Assessment Questionnaire    
  (J-HAQ) score   
Malhan S (42) 2010 (Turkey) Per patient annual direct costs: - Total direct costs: Evaluation of direct healthcare costs, using 
  €2,669.14 - Out-patient costs: €240.40 - Cost for single reimbursement agencies perspective 
  hospital stay: €87.76 - Costs per medication: €2,238   
Flipon E (44) 2009 (France) Per patient annual costs: - €5,928 in RA patients Evaluation of direct medical + indirect RA 
  - €2,424 in patients with undifferentiated arthritis attributable costs (2003 data)  
  - Early predictors of increased total costs (p<0.05): higher
  pain and presence of rheumatoid factor   
Joyce AT (45) 2009 (USA) Per patient annual direct costs: - RA+CVD patients:  Evaluation of direct healthcare costs in patients
  US$14,145 - RA+CVD+depression: US$13,513 with RA with or without comorbidities (CVD: 
  - RA+depression: US$12,225 - RA alone: US$11,404 comorbid cardiovascular disease, Dep: depression)
Silverman S (46) 2009 (USA) Per patient annual direct costs: - RA patients: US$10,716 Evaluation of direct healthcare costs in patients  
  - FM patients: US$10,911 - RA+FM patients: US$19,395 with RA, ﬁbromyalgia (FM), or both conditions
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Europe). Per-patient annual costs were 
around €21,000 in the US and €13,500 
in Europe (Fig. 2 shows costs for US 
and larger European countries). In Eu-
rope, medical costs accounted for about 
one-third of overall expenditure; the 
majority of costs were direct costs (49% 
of total costs), production losses (32%) 
and informal care (19%). Costs in the 
United States were considerably higher 
than in Europe, due to a higher use of 
biological DMARDs. Results high-
lighted relevant cost variability across 
countries, potentially attributable to dif-
ferent factors: i) proportions of patients 
treated with biological drugs, ii) differ-
ences among patients on disease sever-
ity, level of comorbidity. 
Several studies have demonstrated that 
disease severity and functional disabili-
ty are signiﬁcant predictors of increased 
direct and indirect costs in RA popula-
tion. Lundkvist et al. (2) highlight the 
importance to correlate RA costs to the 
year of publication. In more recent cost-
of-illness studies, enrolled patients had 
a higher likelihood to be treated with 
new, high cost, biological therapies, 
compared to older studies in which 
more RA patients were treated with tra-
ditional DMARDS (e.g. methotrexate). 
Many recent cost-of-illness studies 
were focused on the inﬂuence of new 
generation treatment with biologi-
cal agents (e.g. anti-TNF, rituximab, 
abatacept) on healthcare direct costs 
for patients with RA (51, 59, 77, 135). 
Several studies evaluating direct medi-
cal costs found that introduction of 
biological treatments for RA has in-
creased drug-related costs (59), but re-
duced the rate of out-patient visits and 
hospital admissions (135). Finally, the 
adoption of more complex patterns of 
treatment such as anti-TNF switching 
or usage of other biologic agents after 
anti-TNF failure, has led to a rapid in-
crease of overall higher medical costs 
compared to the previous decade. A 
study conducted in 2011 in the USA 
(19) revealed that switching from one 
anti-TNF drug to another during the 
ﬁrst year of treatment, would cost more 
than maintaining patients on the same 
anti-TNF therapy as annual RA-re-
lated prescription drug costs ($8,340 
vs. $7,058; p=0.012), RA-related 
healthcare costs ($15,048 vs. $13,312; 
p=0.008), and total healthcare costs 
($26,697 vs. $21,381; p<0.001).
March LM (48) 2008 (Australia) Qualitative assessment: - Reduction of out-of-pocket costs  Evaluation of out-of-pocket expenditure (patient’s
  and service utilisation during the ﬁrst year after TKR and perspective) in RA patients undergoing total knee 
  THR patients replacement (TKR) or total hip replacement (THR)  
   surgery 
Kobelt G (49) 2008 (France) Per patient annual costs: - Direct healthcare costs in societal Evaluation of direct medical + non-medical + 
  perspective (health insurance + patient): €11,757 indirect costs (societal perspective) 
  - Direct costs in health insurance perspective (€9,216) 
  - Direct non-medical costs in societal perspective (health
  insurance + patient):  €11,757  
Favalli EG (51) 2008 (Italy) Per patient annual treatment costs: - Without vial Evaluation of treatment costs in RA patients 
  optimisation: €8,454.65 - With vial optimisation (reducing receiving a biological therapy (inﬂiximab) 
  drug wastage): €7,505.85   
Chermont GC (52) 2008 (Brazil) Per patient annual costs: - Total costs: US$424.14 - Direct Evaluation of direct + indirect costs for RA patients 
  costs: 95% of total costs - Drug costs: 59% of total costs and health public service (societal perspective) 
  - Indirect costs: 5% of total costs   
Al MJ (53) 2008 (Netherlands) Per patient 6-months treatment costs: - Celecoxib: €255 Evaluation of treatment costs in RA patients  
  - NSAIDs: €166 - NSAID+misoprostol: €285 receiving celecoxib, nonsteroidal 
  - NSAID+H(2)RA: €284 - NSAID+PPI: €243 - Arthrotec: anti-inﬂammatory drugs (NSAIDs), alone or in 
  €187 combination with gastro-intestinal drugs 
   (misoprostol, histamine-2 receptor antagonists:  
   H(2)RA; proton pump inhibitors: PPI, Arthrotec)
Khanna R (55) 2007 (USA) Medical costs covered by Medicare: - $2,379 per year Evaluation of resources consumption and medical
  Patients with >1 prescription: - Narcotic analgesic: 67.8% services covered by Medicare in RA US patients 
  - Nonsteroidal anti-inﬂammatory drugs: 58.8% 
  - Oral steroid: 48.3% - Disease-modifying anti-rheumatic 
  drug: 40.1% - Biologic agent: 12.4%  
Lundkvist J (2) 2008 (Multi-countries) Total health costs:- €45.3 billion/year in Europe Review of RA cost-of-illness studies measuring
  - €41.6 billion/year in the US  direct and/or indirect costs, or evaluating overall  
   economic burden
Juillard-Condat B (59) 2007 (France) Annual RA costs: - Total costs: €15,148.57 after etanercept Evaluation of direct + indirect costs for RA 
  initiation - Total costs: €5,248.95 prior to etanercept patients, prior and after treatment initiation with 
  initiation  - Drug costs: €9,995.23 after etanercept initiation etanercept 
  - Drug costs: €120.12 prior to etanercept initiation - No 
  difference between indirect costs before and after therapy 
  initiation       
Jacobsson LT (61) 2007 (Sweden) Annual RA costs:  - Total costs: €12,020 - Direct costs: Evaluation of direct + indirect costs for RA 
  41% of total costs (mainly drugs,  community services and patients (2002 data) 
  hospitalisations   
*Data taken from abstracts of selected articles. 
Main Author Year of publication Summary of results Methodological notes 
 (Country) 
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Table III. Main ﬁndings from studies evaluating indirect costs in RA*.
Main Author Year of publication Lost working days: Economic impact of  Effects on working rate Methodological notes
 (Country) summary of results  productivity loss:summary retirement/disability 
   of results pensions: summary of results  
Simons WR (13) 2012 (USA) Lost working days attributable Reduction of annual Rate of employment in RA Evaluation of working status 
  to RA: - 4.86 days: year I -  income: - $2,404: year I patients: - 36.8%: year I and productivity loss during 
  1.70 days: year II - 2.99 days - $2,207: year II  - $1,212: - 39.5%: year II - 44.0%: three consecutive years
   year III year III year III   
Hallert E (27) 2012 (Sweden)     Rate of disability pensions Evaluation of disability 
    (DP): - 1990: 1.9% of total pensions attributable to RA 
    DPs - 2000: 1.5% of total over three decades, using the 
    DPs - 2009: 1.0% of total DPs Swedish National Social 
     Insurance Register 
Aceves-Avila FJ (63) 2011 (Mexico) Lost working days   Evaluation of effect 
  (per-month), attributable to   medication errors on 
  medication errors: - 3   productivity loss, in 
  days/month     rheumatology patients 
     (292 out of 381 had RA) 
Langley PC (18) 2011 (China)     Likelihood of workforce National survey evaluating 
    participation: - About 8%  QoL and workforce 
     participation in RA patients
Neovius M (64) 2011 (Sweden) Annual sick leave and  Rate of disability pensions Evaluation of sick leave and 
  disability pension days:  (DP), before therapy disability pension rates from 
  - DMARD monotherapy:  initiation: - DMARD national registers, over the 
  78 days - DMARD  monotherapy: 10% - DMARD period  1999-2007 (RA 
  combination: 132 days -   combination: 12% - population stratiﬁed by type
  Biological therapies: 190 days   Biological therapies: 43% of therapy)
Neovius M (65) 2011 (Sweden) Annual sick leave and   Comparison of progression of  
  disability pension days: - 43   sick leave and disability 
  days/year: year I from   pension rates over time, from 
  diagnosis - 77 days/year: year   national registers, in RA 
  II from diagnosis - 147   patients diagnosed during the 
  days/year: year III from   period 1999-2007 
  diagnosis - 116 days/year: 
  year III from diagnosis         
Zhu TY (26) 2011 (Hong Kong)    Per patient annual costs: Per patient annual costs:  Longitudinal evaluation 
   - Total costs: US$ 9,286 - Total costs: US$ 9,286 (follow-up=10.8 years) of  
   - Indirect costs: 60% of total - Direct costs: 40% of total  direct + indirect costs     
   costs  costs    
Kirchhoff T (28) 2011 (Germany)   Per patient annual  Evaluation of direct medical 
   productivity costs:  + indirect costs (societal 
   - €1,480 in 1997-98;  perspective) in two different 
   €850 in 2002   periods: 1997-98 vs. 2002
   (p<0.05 for the difference)      
Bowman SJ (69) 2010 (UK)   Per patient annual  Model estimation of indirect 
   productivity costs:  costs in three groups of 
   - pSS patients: £7,677  women: RA patients, primary 
   - RA patients: £10,444  Sjögren’s syndrome (pSS)   
   - Community controls: £892    patients, community controls 
Sokka T (70) 2010 (Multi-countries)     Probabilities of continuing Longitudinal evaluation of 
    to work: - 80% at 2 years probabilities of continuing to 
    - 68% at 5 years work in patients with RA
Franke LC (35) 2009 (Netherlands)    Per patient annual costs:  Comparison of direct medical 
   - Total costs in RA: €14,906  + family burden + indirect
   - Indirect costs in RA: more  costs (societal perspective)
    than 50% of total costs  in RA vs. ankylosing 
   - Productivity costs higher if  spondylitis 
   human cost approach adopted
   (vs. friction costs)       
Birnbaum H (72) 2009 (USA)  Per patient annual  Model estimation of indirect 
   productivity costs:  costs in RA patients receiving 
   - Adalimumab: $9,071  adalimumab vs. other RA 
   - Other RA therapies: $16,335   therapies 
   - Cost for reduced productivity:     
   57% of total indirect costs 
   - Costs for absenteeism/
   disability 21% of total indirect  
   costs - Costs job turnover: 21% 
   of total indirect costs     
Hoving JL (73) 2009 (Netherlands)   Per patient weekly  Evaluation of productivity 
   productivity gain vs. baseline:  in RA patients after a 
   - +€169 (p<0.05)  6-months treatment with 
     TNF inhibitors
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Some studies evaluated costs (or re-
source consumption) of RA by disease 
severity/activity. Disease activity pro-
gression was found to predict an in-
crease of costs (21, 41). A French study 
published in 2011 (29) assessed the use 
of direct medical resources, excluding 
drugs, according to level of disease ac-
tivity (using DAS score as the stratiﬁ-
cation variable). Results indicated that 
costs for patients achieving remission 
were €771 over the ﬁrst 6 months 
period and €511 during the next 6 
months period. For patients achiev-
ing a low disease activity state, costs 
were estimated at a €905 for the ﬁrst 
6 months and €696 for each 6 months 
period. Finally, patients still in moder-
ate to high disease activity had higher 
costs (€1,215 for the ﬁrst 6 months). 
In the same year, a similar study con-
ducted in Sweden (27) analysed the re-
lationship between the level of disease 
activity at 3-month follow-up and costs 
over the following 4 years. Patients 
with low disease activity score levels 
incurred relatively low direct costs 
(€2,760 per year 1; €2,447 per year 2; 
€1,693 for year 3 and €2,073 per year 
4) and patients with moderate to high 
disease activity score levels incurred 
higher direct costs (€4,147 per year 1; 
€3,173 per year 2; €3,085 per year 3 
and €3,666 per year 4) independent of 
age and gender.
Some studies have also examined out-
of-pocket expenditure. In Belgium, 
long-standing RA patients (>12 years 
since diagnosis) spent more than twice, 
compared to early-diagnosed RA pa-
tients (<1 year: €1,098 vs. €469: (137, 
study published in 2005, included in 
article ref. 23). Out-of-pocket expendi-
tures were estimated to be AUS$1,523 
per patient per year in Australia; higher 
expenses were seen with increasing 
disability and in women (138, study 
published in 2002, included in article 
ref. 23). A US study linked out-of-
pocket expenditure to health outcomes, 
showing that adherence to drug treat-
ment, particularly for expensive drugs, 
was lower in patients with the highest 
co-payments or co-insurance (47).
Over the past ﬁve years, 45 studies 
reporting the impact of RA on work 
loss and work disability have been 
published. Almost all studies found 
that productivity loss (i.e. absenteeism 
and presenteeism) in RA determines 
relevant expenditure for both employ-
ers and employees, but work disabil-
ity rates and associated indirect costs 
vary across studies. A recent review 
published in 2011 evaluated 12 cross-
sectional and 9 longitudinal studies 
aimed to measure indirect costs or lost 
working days (23). One of the studies 
examined in this review (139) reported 
that RA patients had an increased risk 
to lose working days/retire, compared 
with matched controls (odds ratio; OR: 
1.2–3.4). Three longitudinal studies in 
early RA showed that one of three work-
ing patients voluntarily retired within 
the ﬁrst 2 years after diagnosis, while 
another study found even higher ﬁgures 
(percentage of patients leaving work by 
2.5 years and 6 years from diagnosis: 
40% and 53%, respectively) (140, study 
published in 2007, included in article 
ref. 23). A large US observational study 
on work disability in RA (average du-
ration of follow-up: 12.8 years) found 
an incidence rate of 8.7% for stopping 
work and 4.0% for stopping and not re-
suming work (141, published in 2007, 
included in article ref. 23). 
Estimation of indirect costs depended 
on the approach adopted: loss of pro-
ductivity amounted to €8,452 using 
human capital approach vs. €1,441 
using friction cost approach. Accord-
Zhang W (66) 2008 (Canada) Per patient productivity gain   Evaluation of productivity in 
  vs. baseline: - Absenteeism:   RA patients after a 12-weeks 
  -0.5 workdays per 2  weeks   treatment with adalimumab 
  - Unpaid work productivity: 
  -3.5 workdays per 2 weeks        
de Azevedo AB (76) 2008 (Brazil)   Per patient annual indirect Impact on working status:  Evaluation of indirect costs
   costs: - US$ 2,423.51 - Retired early due to RA: and impact on working 
    24.5% - Sick leave due to RA: status in RA patients 
    32.3%   
Kobelt G (49) 2008 (France)    Per patient annual indirect Impact on working status: Evaluation of direct medical 
   costs: - Total costs: €5,076 - Retired early due to RA: + non- medical + indirect 
   - Indemnity payments: €1,944 34% costs (societal perspective) 
     and working status
Chermont GC (52) 2008 (Brazil)    Per patient annual costs:  Evaluation of direct + 
   - Total costs: US$424.14  indirect costs for RA 
   - Indirect costs: 5% of total  patients and health public 
   costs    service (societal perspective)
Shanahan EM (78) 2008 (Australia)   Personal annual income:   Evaluation of annual
   - RA patients: AUS$22,400  personal income in RA 
   - General population:  patients, compared vs. 
   AUS$38,000   general population
Jacobsson LT (61) 2007 (Sweden)   Annual RA costs:  Evaluation of direct + 
   - Total costs: €12,020  indirect costs for RA  
   - Indirect costs: 59% of total  patients (2002 data)
   costs     
*Data taken from abstracts of selected articles. 
Main Author Year of publication Lost working days: Economic impact of  Effects on working rate Methodological notes
 (Country) summary of results  productivity loss:summary retirement/disability 
   of results pensions: summary of results  
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ing to Lundkvist’s review (2), indirect 
costs were €16.584 billion per year in 
Europe and €8.716 billion per year in 
the US. Per patient annual values were 
quite similar: €4,300 in Europe and 
€4,400 in the US. However, the aver-
age value for Europe is the result of 
very different estimations. In general 
terms, studies conducted in Western 
Europe reported much higher indirect 
costs than Eastern countries. The high-
est value has been reported for Germa-
ny (€11,400), perhaps a country with 
one of the most developed public wel-
fare system. Variability of indirect costs 
across countries might be attributable 
to different reasons, such as social se-
curity systems and welfare, clinic con-
ditions of enrolled patients, duration 
of follow-up, which could realistically 
have affected productivity loss.  
Increasing age, manual work, larger 
impact on physical function (measured 
by the Health Assessment Question-
naire, HAQ), level of co-morbidity and 
duration have been found statistically 
signiﬁcant predictors of increased indi-
rect costs (142, 143 studies published 
prior to 2007, included in article ref. 
75). There were also geographic dif-
ferences, indicating the importance 
of social security systems and unem-
ployment rates. For example, a study 
comparing patients with early RA in 
Finland and the USA found that Finn-
ish patients had higher rates of work 
disability (expressed as probability of 
working at 36 months: 0.84 vs. 0.89; 
p=0.02) despite better scores for pain 
and function. This was attributed to 
less stringent criteria for receiving dis-
ability beneﬁts in Finland (144, study 
published in 2006, included in article 
ref. 75).
Although these methodological issues 
can determine different results, it is ac-
knowledged that RA is strictly related 
to work limitations, high rates of ab-
senteeism and presenteeism. Therefore 
most studies highlight the opportunity 
of including these type of costs and 
adopt a broad economic perspective 
when evaluating the economic burden 
of RA and comparing cost-effective-
ness of different alternatives for patient 
management. 
Quality of Life in RA 
Different generic and speciﬁc quality-
of-life measures have been used to as-
sess RA. The most widely used were 
Short-Form (SF) 36, EuroQoL (EQ-
5D) and the HAQ. RA has a signiﬁcant 
impact on all components of the SF-36. 
The most recent review, published in 
2011, reported 17 observational stud-
ies and 6 randomised controlled trials 
(79) using SF-36 to evaluate the im-
pact of RA on quality of life assessed. 
These results come from data of 5,090 
patients with a mean age of 56 years 
(range 43–64) and mean disease du-
ration of 9.5 years (range <1–16) 
and showed that physical component 
scores (PCSs) were lower than mental 
component scores (MCSs), with the 
exception of vitality. The lowest scores 
were seen for the role physical domain. 
Poorer quality of life scores were as-
sociated with higher disease activity. 
Data from trials have showed that bio-
logical drugs provide greater beneﬁts 
in PCS scores (weighted mean differ-
ence of 4.55: 95% conﬁdence interval 
(CI) 3.80–5.31; p<0.00001) compared 
with MCS scores (weighted mean dif-
ference of 2.59 (95% CI 1.66–3.52, 
p<0.00001). 
The HAQ is widely used in RA because 
of its effectiveness in measuring patient 
function. Total score of the HAQ ranges 
from 0 to 3, with scores of 0–1 indicat-
ing mild/moderate disability, 1–2 mod-
erate/severe disability and 2–3 severe/
very severe disability (145). In RA, an 
improvement of at least 0.22 is consid-
ered indicative of improved functional 
status (146, 147). Moreover, HAQ scor-
ing variations are strongly correlated 
with EQ-5D, SF-6D, and Health Utili-
ties Index (HUI)-3 (148). HAQ scores 
are traditionally increased over time at 
varying rates (Figure 3), although in 
general, at slower rates in recent years. 
HAQ score is high in patients with ac-
tive disease (149, 150), and it lowers 
with the improvement of inﬂammatory 
synovitis. In addition HAQ is affected 
by joint damage with a strong correla-
tion, in established RA, between HAQ 
scores and measures of erosive damage 
(149). Other factors associated with 
higher HAQ scores include depression, 
low socioeconomic status (151, 152) 
and co-morbidities (153).
As the EuroQol is used to evaluate 
health costs, it is interesting to observe 
that this index is closely associated 
with socioeconomic deprivation. An 
analysis of EuroQol scores in a trial of 
intensive DMARD treatment by Harri-
son et al. (155) showed that RA patients 
who have high levels of deprivation 
have low EuroQol scores compared to 
patients with low levels of deprivation. 
There is also strong evidence that Eu-
roQol scores are worse in RA patients 
with multiple co-morbidities (156).
Many studies have evaluated utilities 
to assess QoL in RA patients (18, 84, 
85 98). Moreover, utilities have been 
used in cost-utility analyses comparing 
pharmacological alternatives (38, 108). 
A comparison of utilities across studies 
is extremely complex, due to different 
clinical and demographic characteris-
tics of RA populations. However these 
Fig. 2. Distribution of costs from a recent cost-of-illness review (adapted from 2).
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studies unanimously conﬁrm that RA 
determines a reduction of mean utility 
values compared to general population. 
In their review, Lundkvist et al. (2) 
report a mean utility of 0.500, a value 
quite similar to the utility for chronic 
ischaemic heart diseases and multiple 
sclerosis (0.558 and 0.555 respectively, 
for subjects evaluated in the in-patient 
setting, and worse than conditions such 
as gastro-esophageal reﬂux disease 
(0.671) and non-insulin-dependent dia-
betes mellitus (0.764).
There are limited data about changes 
in EuroQol with disease duration and 
most of the prospective data about 
changes in EuroQol scores focus on 
the effects of drug treatment. A study 
of intensive DMARDs treatment in 
established stable RA by Symmons et 
al. (157, published in 2005, included in 
article ref. 79) showed that there were 
small declines in EuroQol scores over 
3 years, with mean changes of 0.03 per 
year, which is approximately the same 
as the 1% of maximal score annual 
worsening in HAQ. Changes of 0.1–0.2 
of the EuroQol are considered as clini-
cally relevant. The impact of biologics 
on EuroQol scores was shown in an 
observational study carried out in Swe-
den, indicating larger changes with the 
ﬁrst TNF inhibitor compared to second 
and third inhibitors cycle (scores: 0.45, 
0.64, and 0.52 respectively) (154). So 
far there is relatively little information 
about changes in EuroQol in trials of 
biologics.
Cost-effectiveness analyses in RA
The high-cost of new biologic thera-
pies has raised several concerns on 
their prescribing cost-opportunity. In 
particular, health-economists have 
tried to address under which conditions 
(monotherapy vs. combination with 
conventional DMARDs, ﬁrst vs. sec-
ond line treatment) usage of biologics 
is sustainable from an economic view 
point (158), including several system-
atic reviews to assess cost-effective-
ness of different therapeutic strategies 
of RA, including biologic agents (79, 
103, 105). Nevertheless, a clear assess-
ment of cost effectiveness is difﬁcult 
due to the high variability of method-
ologies and approaches used. Results 
vary according to adopted perspective 
(payer perspective vs. societal perspec-
tive), choice of comparators (head-to-
head vs. placebo controlled settings), 
and type of selected patients (e.g. pa-
tients with severe or highly active dis-
ease vs. remitted patients). 
Summarising, the above-mentioned 
reviews suggest that usage of biolog-
ics (mainly TNF antagonists) either 
in monotherapy or in association with 
DMARDs, would not be recommended 
in RA naïve patients, due to high in-
cremental cost-effectiveness ratios vs. 
alternatives (mainly methotrexate and 
other traditional DMARDs), along 
with evidence that similar efﬁcacy with 
small molecule traditional DMARDs is 
seen in 50–80% of patients, and higher 
levels of adverse events are seen with 
biological agents. Feely et al. (34) con-
ﬁrm these ﬁndings, also highlighting 
the importance of early initiation with 
conventional DMARDs to improve 
cost-effectiveness of the intervention.
On the other hand, the usage of these 
new-generation agents (both in mono-
therapy and in combination with MTX) 
is cost-effective compared to DMARDs 
in patients who have failed DMARD 
treatment or for whom DMARDs treat-
ment is contra-indicated, using a will-
ingness to pay threshold of $50,000 per 
QALY (105). However in one of these 
reviews (103), the authors argued that 
cost-effectiveness results were favour-
able for biologics due to the choice of 
drug as second line treatment compa-
rator (in most cases methotrexate, the 
same agent used in ﬁrst line treatment), 
and that more appropriate design should 
be set up to conﬁrm these ﬁndings. Bren-
nan et al. modeled cost-effectiveness of 
anti-TNFs vs. conventional DMARDs 
in patients who failed two traditional 
disease-modifying anti-rheumatic drugs 
(121). Therapy with anti-TNF was 
found cost-effective (£23,882/QALY 
gained for the base case), with 84% 
probability to be below the accepted 
threshold of £30,000. The two main is-
sues, early treatment with conventional 
DMARDs and switch to biologics after 
(at least one) conventional DMARDs 
failure, have been simultaneously 
evaluated by Finckh et al. (113), who 
compared three different therapeutic 
strategies: i) “pyramid” strategy with 
initial nonsteroidal anti-inﬂammatory 
drugs, patient education, pain manage-
ment, and low-dose glucocorticoids, 
and disease-modifying antirheumatic 
drugs (DMARDs) at 1 year for non-
responders; ii) early DMARD therapy 
with methotrexate (159); iii) early ther-
apy with biologics and methotrexate. In 
this study early DMARD treatment was 
more cost-effective (lower ICER) than 
early biologic treatment, vs. pyramid 
strategy, used as reference.
  
Discussion
As all inﬂammatory connective tis-
sue diseases, rheumatoid arthritis is a 
chronic disease with a relevant burden 
for national healthcare services, health-
care providers, and society in general 
Fig. 3. Annual HAQ progression in 14 studies published between 2000 and 2010 (adapted from 79).
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(4-9, 160, 161). Factors like the high 
epidemiological impact, the relatively 
young age at disease onset, the status of 
chronic-degenerative disease, the high 
rate of comorbidities and effects on 
patients’ disability and work productiv-
ity, have drawn payers’ attention over 
the years. The level of attention on this 
condition has increased with the intro-
duction of new therapies, characterised 
by much higher costs than conventional 
DMARDs.
The main ﬁndings of our review can be 
summarised as follows:
• RA is a widespread disease, with an 
average prevalence rate of almost 
0.5–1%, and an overall population 
of around 6.7 million RA patients in 
Europe and North America.
• RA impact on patients’ QoL is con-
siderable, with RA patients regularly 
scoring amongst the groups with 
lowest utility values. Mean utilities 
in population samples of RA patients 
have been estimated at between 0.45 
and 0.55. Only multiple sclerosis ap-
pears to have a similar effect on QoL 
among studied diseases. Moreover 
RA accounts for for 0.8% of all 
DALYs lost in Europe.
• RA-attributable direct health care 
costs have been estimated at €14 bil-
lion per year in Europe. Productivity 
loss expenditure for both employers 
and employees signiﬁcantly contrib-
utes to increase societal costs.
• RA management costs increase with 
increasing disease severity, in par-
ticular with functional disability. In 
the early years from the introduction 
of the biological drugs, utilisation 
patterns rapidly have increased from 
year to year, and the impact of these 
drugs compared with traditional 
DMARDs is considerable.
• Economic evidence suggests that 
biologic agents generally are cost 
effective compared to DMARDs for 
RA in adults in selected populations 
at a willingness to pay threshold of 
$50,000 per QALY.
In the future, health-economic research 
should focus on the evaluation of ac-
quisition costs of biologic agents, and 
should adapt the results to local health-
care settings (162) or designing ad-hoc 
studies taking into account real practice 
data.
The deﬁnition of appropriate time-
frames to adopt biological therapies 
based on clinical manifestations, on 
the identiﬁcation of novel biomarkers 
as well as economic considerations, 
would represent, in the next years, the 
main challenges for health economists 
involved in decision making support in 
RA and other rheumatic diseases (163-
169).
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